Search - tctmd.com

Displaying 161 - 180 of 194

Sort: Relevancy | Date

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

Presentation AHA 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presenter: Gilles Rioufol

November 15, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation TCT 2016

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Samir R. Kapadia

October 30, 2016

Presentation

AHA Late Breaking Trials: What's more appropriate? IVUS or appropriate use criteria?

Presenter: Gregg W. Stone

January 19, 2016

Presentation TCT 2015

Intervention for Tricuspid Regurgitation: What Do the Guidelines Say? (ACC/AHA and ESC/EACTS)

Presenter: Rebecca T. Hahn, Joachim Schofer, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

What Defines Severe MR Post-AHA/ACC Guidelines?

Presenter: Jeroen J. Bax, Paul A. Grayburn

October 15, 2015

Presentation TVT 2015

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Disagree?

Presenter: Gregg W. Stone, Alec S. Vahanian, John D. Carroll

June 05, 2015

Presentation TVT 2015

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Agree?

Presenter: Gregg W. Stone, Alec S. Vahanian, Allan Schwartz

June 05, 2015

Presentation

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Presenter: Gregg W. Stone

December 01, 2014

Presentation AHA 2014

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Presenter: Dean J. Kereiakes

November 16, 2014

Presentation AHA 2014

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Presenter: C.Kaiser

November 16, 2014

Presentation AHA 2014

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Presenter: S. van Diepen

November 16, 2014

Presentation TCT 2014

Guideline Update: Aortic and Mitral Valve Disease and the 2014 AHA/ACC Guideline for Valvular Heart Disease

Presenter: Blase A. Carabello, George D. Dangas, Patrick T. O'Gara

September 15, 2014

Presentation TCT 2014

ASA/AHA Guidelines 2014: PFO Closure for Cryptogenic Stroke Is Now Class III LOE A! Is This the Final Word from the Neurology Community?

Presenter: Matthew J. Price, Mark Reisman, Sheldon Goldberg, David E. Thaler

September 13, 2014

Presentation TCT 2014

Important Changes in the New 2014 ACC/AHA Aortic Valve Guidelines: Aligning Definitions of Aortic Stenosis Severity with Treatment Recommendations

Presenter: A. Pieter Kappetein, Martin B. Leon, Howard C. Herrmann, Robert O. Bonow

September 13, 2014

Presentation TVT 2014

2014 ACC/AHA Aortic Valve Guidelines: Aligning Definitions of Aortic Stenosis Severity with Treatment Recommendations

Presenter: Catherine M. Otto

June 05, 2014

Presentation

Post-AHA 2013 CME Webcast: CORAL and ERASE

Presenter: William Gray

November 24, 2013

Presentation TCT 2013

Introduction and AHA Policy Statement

Presenter: H. Robert Superko

October 31, 2013

Presentation

Mini-Review of the Latest ACC/AHA and ESC Guidelines on DAPT and PCI

Presenter: Stephan Windecker

October 29, 2013

Advertisement

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

FUnctional Testing Underlying REvascularization: The FUTURE trial

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

AHA Late Breaking Trials: What's more appropriate? IVUS or appropriate use criteria?

Intervention for Tricuspid Regurgitation: What Do the Guidelines Say? (ACC/AHA and ESC/EACTS)

What Defines Severe MR Post-AHA/ACC Guidelines?

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Disagree?

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Agree?

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Guideline Update: Aortic and Mitral Valve Disease and the 2014 AHA/ACC Guideline for Valvular Heart Disease

ASA/AHA Guidelines 2014: PFO Closure for Cryptogenic Stroke Is Now Class III LOE A! Is This the Final Word from the Neurology Community?

Important Changes in the New 2014 ACC/AHA Aortic Valve Guidelines: Aligning Definitions of Aortic Stenosis Severity with Treatment Recommendations

2014 ACC/AHA Aortic Valve Guidelines: Aligning Definitions of Aortic Stenosis Severity with Treatment Recommendations

Post-AHA 2013 CME Webcast: CORAL and ERASE

Introduction and AHA Policy Statement

Mini-Review of the Latest ACC/AHA and ESC Guidelines on DAPT and PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content